AxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.
| Revenue (TTM) | $238.10M |
| Gross Profit (TTM) | $178.61M |
| EBITDA | $-2.13M |
| Operating Margin | -4.61% |
| Return on Equity | -18.00% |
| Return on Assets | -2.32% |
| Revenue/Share (TTM) | $5.00 |
| Book Value | $4.61 |
| Price-to-Book | 9.99 |
| Price-to-Sales (TTM) | 9.55 |
| EV/Revenue | 9.93 |
| EV/EBITDA | 4083.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 26.60% |
| Shares Outstanding | $53.18M |
| Float | $52.02M |
| % Insiders | 2.19% |
| % Institutions | 94.75% |
Volatility is currently expanding
AxoGen NASDAQ: AXGN President and CEO Michael Dale said the company's growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified.
ALACHUA, Fla. and TAMPA, Fla.
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago.
ALACHUA, Fla. and TAMPA, Fla.
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ALACHUA, Fla. and TAMPA, Fla.
